SNPMiner Trials by Shray Alag


SNPMiner Trials: Clinical Trial Report


Report for Clinical Trial NCT01259050

Developed by Shray Alag, 2019.
SNP Clinical Trial Gene

Phase 1 Open Label Study of Zinc Therapy in ALS Patients

The purpose of this study is to determine the safety of Zinc given at 90mg/d in conjunction with 2mg/d of copper in ALS patients.

NCT01259050 Amyotrophic Lateral Sclerosis
MeSH: Motor Neuron Disease Amyotrophic Lateral Sclerosis
HPO: Abnormal anterior horn cell morphology Amyotrophic lateral sclerosis

1 Interventions

Name: Zinc and Copper

Description: Optizinc 90 mg/d Copper 1 mg

Type: Drug

Zinc and Copper


Primary Outcomes

Measure: To evaluate the safety of high doses of zinc in patients with ALS

Time: 1 year

Secondary Outcomes

Measure: Measure levels of BMAA in blood and urine to determine if there is a decline in these levels over the course of treatment

Time: 1 year

Purpose: Treatment

Allocation: Randomized

Single Group Assignment


There is one SNP

SNPs


1 G93A

Previous studies have shown that in ALS mutant G93A SOD transgenic mice, actual zinc supplementation delayed death. --- G93A ---



HPO Nodes


HPO:
Abnormal anterior horn cell morphology
Genes 12
CPLANE1 VRK1 IGHMBP2 UBA1 TFG SOD1 SETX CEP126 ASAH1 GLE1 SMN1 ATXN3
Amyotrophic lateral sclerosis
Genes 44
VAPB TREM2 CCNF PON1 PON2 PON3 NEFH DAO PPARGC1A TARDBP NEK1 ALS2 SPG11 ERBB4 CHCHD10 TAF15 OPTN SETX FUS UBQLN2 ANG PSEN1 C9ORF72 PFN1 DCTN1 ATXN2 FIG4 SIGMAR1 MAPT HNRNPA1 GLE1 HNRNPA2B1 TUBA4A SQSTM1 UNC13A CFAP410 MATR3 TBK1 ANXA11 SOD1 VCP CHMP2B EPHA4 PRPH